Psoriasis Skin and Connective Tissue Diseases
Conditions
Interventions
The study will last 24 weeks. All volunteers will continue with their usual treatment and have an equal chance of being randomly allocated to the MOVE SMART group using a stratified randomisation proc
Sponsors
University of Manchester
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Patients with Type 1 chronic plaque psoriasis (disease onset before age 40 years) with/without stable psoriatic arthritis 2. Aged 18-60 years (due to the prevalence of CVD disease in the >60s in the UK, which means that we are likely to detect greater differences in CVD risk in those 8 hours per day
Exclusion criteria
Exclusion criteria: 1. Unable to rise from a sitting to a standing position, walk around a room (independently or aided by a walking stick, frame or trolly) whilst maintaining a steady pace (~30 steps/minute) for 2 minutes without stopping. 2. Worsening inflammatory arthritis or the presence of other significant comorbid conditions that would interfere with the ability to participate in physical activity or the study protocol, such as severe cardiovascular disease, severe chronic obstructive pulmonary disease (COPD), or any other condition as determined via the health questionnaire. 3. Regularly engaging in HIGH levels of physical activity (as defined by IPAQ) whilst spending MINIMAL time in sedentary activities during day-waking hours (as calculated by IPAQ,<6 hours per day).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical utility in the management of psoriasis measured using the Psoriasis Area and Severity Index (PASI) self-assessment questionnaire at baseline, week 12 and week 24 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Feasibility of the research processes and delivery of the intervention measured via: 1.1. Recruitment rate measured using a tally of participants recruited to study in the collected study data at baseline and week 24 1.2. Retention rate measured using a tally of participants starting and completing the study in the collected study data at week 24 1.3. Total clinical assessments completed measured using the following self-assessment questionnaires at baseline, week 12 and week 24: 1.3.1. Psoriasis Area and Severity Index (PASI) 1.3.2. Dermatology Life Quality Index (DLQI) 1.3.3. Pittsburgh Sleep Quality Index (P Sleep QI) 1.3.4. Routine Assessment of Patient Index Data 3 (RAPID3) 1.3.5. Psoriatic Arthritis Impact of Disease 12-item (PsAID12) 1.3.6. EuroQol 5-Dimension 5-Level (EQ 5D 5L) 1.4. Capillary-blood self-collection completed measured using a tally of blood collection returns received by the study team in the collected study data at baseline, week 12 and week 24 1.5. Adherence to intervention measured using an accelerometer over 1 week to count activity and sedentary time at baseline, week 6, week 12 and week 24 2. Acceptability of the intervention measured using the 5-point Likert score from the phase 1 survey at week 12 3. Acceptability of the trial processes measured using the 5-point Likert score from the phase 2 survey at week 24 | — |
Countries
England, United Kingdom
Contacts
Public ContactRuss Cowper
Outcome results
None listed